nodes	percent_of_prediction	percent_of_DWPC	metapath
Vandetanib—VEGFA—Gliclazide—type 2 diabetes mellitus	0.204	0.588	CbGbCtD
Vandetanib—SRC—type 2 diabetes mellitus	0.119	0.342	CbGaD
Vandetanib—VEGFA—type 2 diabetes mellitus	0.0945	0.272	CbGaD
Vandetanib—EGFR—type 2 diabetes mellitus	0.0798	0.23	CbGaD
Vandetanib—CYP3A4—type 2 diabetes mellitus	0.0291	0.0838	CbGaD
Vandetanib—ALB—type 2 diabetes mellitus	0.0254	0.0731	CbGaD
Vandetanib—ORM1—Nateglinide—type 2 diabetes mellitus	0.0205	0.0589	CbGbCtD
Vandetanib—ALB—Gliclazide—type 2 diabetes mellitus	0.0134	0.0384	CbGbCtD
Vandetanib—ABCC1—Glyburide—type 2 diabetes mellitus	0.0126	0.0363	CbGbCtD
Vandetanib—ALB—Repaglinide—type 2 diabetes mellitus	0.0126	0.0361	CbGbCtD
Vandetanib—ALB—Rosiglitazone—type 2 diabetes mellitus	0.0105	0.0302	CbGbCtD
Vandetanib—ALB—Valsartan—type 2 diabetes mellitus	0.00926	0.0267	CbGbCtD
Vandetanib—ALB—Nateglinide—type 2 diabetes mellitus	0.00861	0.0248	CbGbCtD
Vandetanib—ABCG2—Glyburide—type 2 diabetes mellitus	0.00843	0.0243	CbGbCtD
Vandetanib—ALB—Glyburide—type 2 diabetes mellitus	0.00581	0.0167	CbGbCtD
Vandetanib—CYP3A4—Linagliptin—type 2 diabetes mellitus	0.00552	0.0159	CbGbCtD
Vandetanib—ALB—Losartan—type 2 diabetes mellitus	0.00532	0.0153	CbGbCtD
Vandetanib—CYP3A4—Sitagliptin—type 2 diabetes mellitus	0.00492	0.0142	CbGbCtD
Vandetanib—CYP3A4—Glipizide—type 2 diabetes mellitus	0.0045	0.013	CbGbCtD
Vandetanib—CYP3A4—Repaglinide—type 2 diabetes mellitus	0.00394	0.0113	CbGbCtD
Vandetanib—CYP3A4—Pioglitazone—type 2 diabetes mellitus	0.00356	0.0102	CbGbCtD
Vandetanib—CYP3A4—Nateglinide—type 2 diabetes mellitus	0.0027	0.00776	CbGbCtD
Vandetanib—CYP3A4—Irbesartan—type 2 diabetes mellitus	0.00259	0.00744	CbGbCtD
Vandetanib—CYP3A4—Orlistat—type 2 diabetes mellitus	0.00259	0.00744	CbGbCtD
Vandetanib—CYP3A4—Bromocriptine—type 2 diabetes mellitus	0.00245	0.00704	CbGbCtD
Vandetanib—BMPR1B—peripheral nervous system—type 2 diabetes mellitus	0.0019	0.0338	CbGeAlD
Vandetanib—RET—autonomic nervous system—type 2 diabetes mellitus	0.00183	0.0326	CbGeAlD
Vandetanib—CYP3A4—Glyburide—type 2 diabetes mellitus	0.00182	0.00525	CbGbCtD
Vandetanib—CYP3A4—Losartan—type 2 diabetes mellitus	0.00167	0.0048	CbGbCtD
Vandetanib—ERBB3—peripheral nervous system—type 2 diabetes mellitus	0.00143	0.0254	CbGeAlD
Vandetanib—KDR—hindlimb—type 2 diabetes mellitus	0.00126	0.0225	CbGeAlD
Vandetanib—FLT4—endothelium—type 2 diabetes mellitus	0.000995	0.0177	CbGeAlD
Vandetanib—RIPK2—endothelium—type 2 diabetes mellitus	0.000989	0.0176	CbGeAlD
Vandetanib—TEK—artery—type 2 diabetes mellitus	0.000947	0.0168	CbGeAlD
Vandetanib—SRC—artery—type 2 diabetes mellitus	0.000841	0.015	CbGeAlD
Vandetanib—TEK—endothelium—type 2 diabetes mellitus	0.0008	0.0142	CbGeAlD
Vandetanib—KDR—artery—type 2 diabetes mellitus	0.000774	0.0138	CbGeAlD
Vandetanib—SRC—endothelium—type 2 diabetes mellitus	0.000711	0.0126	CbGeAlD
Vandetanib—KDR—endothelium—type 2 diabetes mellitus	0.000654	0.0116	CbGeAlD
Vandetanib—EPHA5—retina—type 2 diabetes mellitus	0.000626	0.0111	CbGeAlD
Vandetanib—STK35—islet of Langerhans—type 2 diabetes mellitus	0.00061	0.0109	CbGeAlD
Vandetanib—Afatinib—EGFR—type 2 diabetes mellitus	0.000594	0.219	CrCbGaD
Vandetanib—RIPK2—islet of Langerhans—type 2 diabetes mellitus	0.000563	0.01	CbGeAlD
Vandetanib—VEGFA—islet of Langerhans—type 2 diabetes mellitus	0.000561	0.00998	CbGeAlD
Vandetanib—IRAK4—islet of Langerhans—type 2 diabetes mellitus	0.000549	0.00978	CbGeAlD
Vandetanib—RIPK2—retina—type 2 diabetes mellitus	0.000481	0.00856	CbGeAlD
Vandetanib—SLK—islet of Langerhans—type 2 diabetes mellitus	0.000479	0.00852	CbGeAlD
Vandetanib—BMPR1B—adipose tissue—type 2 diabetes mellitus	0.000458	0.00814	CbGeAlD
Vandetanib—MAP4K5—islet of Langerhans—type 2 diabetes mellitus	0.000455	0.0081	CbGeAlD
Vandetanib—RIPK2—nephron tubule—type 2 diabetes mellitus	0.000453	0.00806	CbGeAlD
Vandetanib—VEGFA—nephron tubule—type 2 diabetes mellitus	0.000452	0.00804	CbGeAlD
Vandetanib—FLT3—cardiovascular system—type 2 diabetes mellitus	0.000451	0.00802	CbGeAlD
Vandetanib—FMO1—nephron tubule—type 2 diabetes mellitus	0.000449	0.008	CbGeAlD
Vandetanib—EPHB6—islet of Langerhans—type 2 diabetes mellitus	0.000435	0.00774	CbGeAlD
Vandetanib—ERBB3—nephron tubule—type 2 diabetes mellitus	0.000434	0.00772	CbGeAlD
Vandetanib—MKNK1—retina—type 2 diabetes mellitus	0.000432	0.00769	CbGeAlD
Vandetanib—STK35—pancreas—type 2 diabetes mellitus	0.000429	0.00763	CbGeAlD
Vandetanib—AXL—retina—type 2 diabetes mellitus	0.000425	0.00757	CbGeAlD
Vandetanib—YES1—islet of Langerhans—type 2 diabetes mellitus	0.00042	0.00748	CbGeAlD
Vandetanib—Erlotinib—EGFR—type 2 diabetes mellitus	0.00042	0.155	CrCbGaD
Vandetanib—FLT4—cardiovascular system—type 2 diabetes mellitus	0.000409	0.00728	CbGeAlD
Vandetanib—RIPK2—cardiovascular system—type 2 diabetes mellitus	0.000407	0.00724	CbGeAlD
Vandetanib—SRC—islet of Langerhans—type 2 diabetes mellitus	0.000404	0.00719	CbGeAlD
Vandetanib—FMO1—kidney—type 2 diabetes mellitus	0.000395	0.00703	CbGeAlD
Vandetanib—VEGFA—pancreas—type 2 diabetes mellitus	0.000394	0.00702	CbGeAlD
Vandetanib—FLT4—cortex of kidney—type 2 diabetes mellitus	0.00039	0.00694	CbGeAlD
Vandetanib—STK35—adipose tissue—type 2 diabetes mellitus	0.000389	0.00692	CbGeAlD
Vandetanib—VEGFA—cortex of kidney—type 2 diabetes mellitus	0.000387	0.00688	CbGeAlD
Vandetanib—SLK—nephron tubule—type 2 diabetes mellitus	0.000386	0.00686	CbGeAlD
Vandetanib—Bosutinib—SRC—type 2 diabetes mellitus	0.000385	0.142	CrCbGaD
Vandetanib—FMO1—cortex of kidney—type 2 diabetes mellitus	0.000385	0.00684	CbGeAlD
Vandetanib—ERBB3—kidney—type 2 diabetes mellitus	0.000381	0.00678	CbGeAlD
Vandetanib—ABL2—adipose tissue—type 2 diabetes mellitus	0.000379	0.00675	CbGeAlD
Vandetanib—ERBB3—pancreas—type 2 diabetes mellitus	0.000379	0.00674	CbGeAlD
Vandetanib—FYN—nephron tubule—type 2 diabetes mellitus	0.000375	0.00667	CbGeAlD
Vandetanib—VEGFA—Glyburide—Glimepiride—type 2 diabetes mellitus	0.00037	0.155	CbGdCrCtD
Vandetanib—VEGFA—Glyburide—Tolazamide—type 2 diabetes mellitus	0.00037	0.155	CbGdCrCtD
Vandetanib—EGFR—adipose tissue—type 2 diabetes mellitus	0.00037	0.00659	CbGeAlD
Vandetanib—MKNK1—cardiovascular system—type 2 diabetes mellitus	0.000366	0.00651	CbGeAlD
Vandetanib—FGR—cardiovascular system—type 2 diabetes mellitus	0.000361	0.00643	CbGeAlD
Vandetanib—FLT4—adipose tissue—type 2 diabetes mellitus	0.000361	0.00642	CbGeAlD
Vandetanib—AXL—cardiovascular system—type 2 diabetes mellitus	0.00036	0.0064	CbGeAlD
Vandetanib—YES1—retina—type 2 diabetes mellitus	0.000359	0.00639	CbGeAlD
Vandetanib—RIPK2—adipose tissue—type 2 diabetes mellitus	0.000359	0.00638	CbGeAlD
Vandetanib—VEGFA—adipose tissue—type 2 diabetes mellitus	0.000358	0.00637	CbGeAlD
Vandetanib—FMO1—adipose tissue—type 2 diabetes mellitus	0.000356	0.00633	CbGeAlD
Vandetanib—RET—kidney—type 2 diabetes mellitus	0.000353	0.00629	CbGeAlD
Vandetanib—VEGFA—Glyburide—Gliclazide—type 2 diabetes mellitus	0.000351	0.147	CbGdCrCtD
Vandetanib—VEGFA—Glyburide—Glipizide—type 2 diabetes mellitus	0.000351	0.147	CbGdCrCtD
Vandetanib—IRAK4—adipose tissue—type 2 diabetes mellitus	0.00035	0.00623	CbGeAlD
Vandetanib—MKNK1—cortex of kidney—type 2 diabetes mellitus	0.000348	0.0062	CbGeAlD
Vandetanib—SRC—retina—type 2 diabetes mellitus	0.000346	0.00615	CbGeAlD
Vandetanib—ERBB3—adipose tissue—type 2 diabetes mellitus	0.000343	0.00611	CbGeAlD
Vandetanib—AXL—cortex of kidney—type 2 diabetes mellitus	0.000343	0.0061	CbGeAlD
Vandetanib—YES1—nephron tubule—type 2 diabetes mellitus	0.000338	0.00602	CbGeAlD
Vandetanib—FYN—cardiovascular system—type 2 diabetes mellitus	0.000337	0.00599	CbGeAlD
Vandetanib—SLK—pancreas—type 2 diabetes mellitus	0.000337	0.00599	CbGeAlD
Vandetanib—SLK—cortex of kidney—type 2 diabetes mellitus	0.00033	0.00587	CbGeAlD
Vandetanib—FYN—kidney—type 2 diabetes mellitus	0.000329	0.00586	CbGeAlD
Vandetanib—TEK—cardiovascular system—type 2 diabetes mellitus	0.000329	0.00585	CbGeAlD
Vandetanib—LYN—liver—type 2 diabetes mellitus	0.000326	0.0058	CbGeAlD
Vandetanib—MKNK1—adipose tissue—type 2 diabetes mellitus	0.000323	0.00574	CbGeAlD
Vandetanib—TEK—kidney—type 2 diabetes mellitus	0.000322	0.00573	CbGeAlD
Vandetanib—PDGFRB—islet of Langerhans—type 2 diabetes mellitus	0.000322	0.00573	CbGeAlD
Vandetanib—VEGFA—Glyburide—Chlorpropamide—type 2 diabetes mellitus	0.000321	0.134	CbGdCrCtD
Vandetanib—FYN—cortex of kidney—type 2 diabetes mellitus	0.000321	0.00571	CbGeAlD
Vandetanib—MAP4K5—pancreas—type 2 diabetes mellitus	0.00032	0.00569	CbGeAlD
Vandetanib—TEK—pancreas—type 2 diabetes mellitus	0.00032	0.00569	CbGeAlD
Vandetanib—FGR—adipose tissue—type 2 diabetes mellitus	0.000319	0.00567	CbGeAlD
Vandetanib—LCK—adipose tissue—type 2 diabetes mellitus	0.000319	0.00567	CbGeAlD
Vandetanib—KDR—retina—type 2 diabetes mellitus	0.000318	0.00566	CbGeAlD
Vandetanib—AXL—adipose tissue—type 2 diabetes mellitus	0.000317	0.00564	CbGeAlD
Vandetanib—MAP4K5—cortex of kidney—type 2 diabetes mellitus	0.000314	0.00558	CbGeAlD
Vandetanib—TEK—cortex of kidney—type 2 diabetes mellitus	0.000314	0.00558	CbGeAlD
Vandetanib—FMO3—adipose tissue—type 2 diabetes mellitus	0.000308	0.00547	CbGeAlD
Vandetanib—SLK—adipose tissue—type 2 diabetes mellitus	0.000305	0.00543	CbGeAlD
Vandetanib—STK10—cardiovascular system—type 2 diabetes mellitus	0.000301	0.00536	CbGeAlD
Vandetanib—EPHB6—cortex of kidney—type 2 diabetes mellitus	0.0003	0.00533	CbGeAlD
Vandetanib—KDR—nephron tubule—type 2 diabetes mellitus	0.000299	0.00533	CbGeAlD
Vandetanib—YES1—kidney—type 2 diabetes mellitus	0.000297	0.00529	CbGeAlD
Vandetanib—FYN—adipose tissue—type 2 diabetes mellitus	0.000297	0.00528	CbGeAlD
Vandetanib—YES1—pancreas—type 2 diabetes mellitus	0.000295	0.00526	CbGeAlD
Vandetanib—STK10—kidney—type 2 diabetes mellitus	0.000295	0.00524	CbGeAlD
Vandetanib—SRC—cardiovascular system—type 2 diabetes mellitus	0.000292	0.0052	CbGeAlD
Vandetanib—MAP4K5—adipose tissue—type 2 diabetes mellitus	0.00029	0.00516	CbGeAlD
Vandetanib—TEK—adipose tissue—type 2 diabetes mellitus	0.00029	0.00516	CbGeAlD
Vandetanib—YES1—cortex of kidney—type 2 diabetes mellitus	0.00029	0.00515	CbGeAlD
Vandetanib—ABL1—islet of Langerhans—type 2 diabetes mellitus	0.000287	0.0051	CbGeAlD
Vandetanib—SRC—kidney—type 2 diabetes mellitus	0.000286	0.00509	CbGeAlD
Vandetanib—SRC—pancreas—type 2 diabetes mellitus	0.000284	0.00506	CbGeAlD
Vandetanib—FLT3—liver—type 2 diabetes mellitus	0.000279	0.00496	CbGeAlD
Vandetanib—EPHB6—adipose tissue—type 2 diabetes mellitus	0.000277	0.00493	CbGeAlD
Vandetanib—STK35—liver—type 2 diabetes mellitus	0.000273	0.00486	CbGeAlD
Vandetanib—MAP2K5—cardiovascular system—type 2 diabetes mellitus	0.000269	0.00478	CbGeAlD
Vandetanib—KDR—cardiovascular system—type 2 diabetes mellitus	0.000269	0.00478	CbGeAlD
Vandetanib—YES1—adipose tissue—type 2 diabetes mellitus	0.000268	0.00477	CbGeAlD
Vandetanib—ABL2—liver—type 2 diabetes mellitus	0.000266	0.00473	CbGeAlD
Vandetanib—STK10—adipose tissue—type 2 diabetes mellitus	0.000266	0.00472	CbGeAlD
Vandetanib—KDR—kidney—type 2 diabetes mellitus	0.000263	0.00468	CbGeAlD
Vandetanib—Gefitinib—EGFR—type 2 diabetes mellitus	0.000263	0.0968	CrCbGaD
Vandetanib—EGFR—liver—type 2 diabetes mellitus	0.00026	0.00462	CbGeAlD
Vandetanib—Bosutinib—EGFR—type 2 diabetes mellitus	0.000259	0.0953	CrCbGaD
Vandetanib—SRC—adipose tissue—type 2 diabetes mellitus	0.000258	0.00459	CbGeAlD
Vandetanib—MAP2K5—cortex of kidney—type 2 diabetes mellitus	0.000256	0.00456	CbGeAlD
Vandetanib—KDR—cortex of kidney—type 2 diabetes mellitus	0.000256	0.00456	CbGeAlD
Vandetanib—VEGFA—Enalapril—Nateglinide—type 2 diabetes mellitus	0.000256	0.107	CbGdCrCtD
Vandetanib—FLT4—liver—type 2 diabetes mellitus	0.000253	0.0045	CbGeAlD
Vandetanib—RIPK2—liver—type 2 diabetes mellitus	0.000252	0.00448	CbGeAlD
Vandetanib—VEGFA—liver—type 2 diabetes mellitus	0.000251	0.00447	CbGeAlD
Vandetanib—FMO1—liver—type 2 diabetes mellitus	0.00025	0.00444	CbGeAlD
Vandetanib—IRAK4—liver—type 2 diabetes mellitus	0.000246	0.00437	CbGeAlD
Vandetanib—ABL1—retina—type 2 diabetes mellitus	0.000245	0.00436	CbGeAlD
Vandetanib—ERBB3—liver—type 2 diabetes mellitus	0.000241	0.00429	CbGeAlD
Vandetanib—MAP2K5—adipose tissue—type 2 diabetes mellitus	0.000237	0.00422	CbGeAlD
Vandetanib—KDR—adipose tissue—type 2 diabetes mellitus	0.000237	0.00422	CbGeAlD
Vandetanib—PDGFRB—cardiovascular system—type 2 diabetes mellitus	0.000233	0.00414	CbGeAlD
Vandetanib—Erlotinib—CYP1A2—type 2 diabetes mellitus	0.000232	0.0854	CrCbGaD
Vandetanib—ABL1—nephron tubule—type 2 diabetes mellitus	0.000231	0.00411	CbGeAlD
Vandetanib—PDGFRB—kidney—type 2 diabetes mellitus	0.000228	0.00405	CbGeAlD
Vandetanib—PDGFRB—pancreas—type 2 diabetes mellitus	0.000226	0.00403	CbGeAlD
Vandetanib—MKNK1—liver—type 2 diabetes mellitus	0.000226	0.00402	CbGeAlD
Vandetanib—FGR—liver—type 2 diabetes mellitus	0.000223	0.00397	CbGeAlD
Vandetanib—LCK—liver—type 2 diabetes mellitus	0.000223	0.00397	CbGeAlD
Vandetanib—AXL—liver—type 2 diabetes mellitus	0.000223	0.00396	CbGeAlD
Vandetanib—PDGFRB—cortex of kidney—type 2 diabetes mellitus	0.000222	0.00395	CbGeAlD
Vandetanib—FMO3—liver—type 2 diabetes mellitus	0.000216	0.00384	CbGeAlD
Vandetanib—ERBB3—Bortezomib—Nateglinide—type 2 diabetes mellitus	0.000215	0.09	CbGdCrCtD
Vandetanib—SLK—liver—type 2 diabetes mellitus	0.000214	0.00381	CbGeAlD
Vandetanib—FYN—liver—type 2 diabetes mellitus	0.000208	0.00371	CbGeAlD
Vandetanib—ABL1—cardiovascular system—type 2 diabetes mellitus	0.000207	0.00369	CbGeAlD
Vandetanib—PDGFRB—adipose tissue—type 2 diabetes mellitus	0.000205	0.00365	CbGeAlD
Vandetanib—MAP4K5—liver—type 2 diabetes mellitus	0.000204	0.00362	CbGeAlD
Vandetanib—TEK—liver—type 2 diabetes mellitus	0.000204	0.00362	CbGeAlD
Vandetanib—ABL1—kidney—type 2 diabetes mellitus	0.000203	0.00361	CbGeAlD
Vandetanib—ABL1—pancreas—type 2 diabetes mellitus	0.000202	0.00359	CbGeAlD
Vandetanib—ABL1—cortex of kidney—type 2 diabetes mellitus	0.000198	0.00352	CbGeAlD
Vandetanib—YES1—liver—type 2 diabetes mellitus	0.000188	0.00334	CbGeAlD
Vandetanib—STK10—liver—type 2 diabetes mellitus	0.000186	0.00331	CbGeAlD
Vandetanib—ABL1—adipose tissue—type 2 diabetes mellitus	0.000183	0.00326	CbGeAlD
Vandetanib—SRC—liver—type 2 diabetes mellitus	0.000181	0.00322	CbGeAlD
Vandetanib—KDR—liver—type 2 diabetes mellitus	0.000166	0.00296	CbGeAlD
Vandetanib—MAP2K5—liver—type 2 diabetes mellitus	0.000166	0.00296	CbGeAlD
Vandetanib—VEGFA—Enalapril—Ramipril—type 2 diabetes mellitus	0.000156	0.0651	CbGdCrCtD
Vandetanib—Erlotinib—CYP3A4—type 2 diabetes mellitus	0.000153	0.0565	CrCbGaD
Vandetanib—ABCC1—cortex of kidney—type 2 diabetes mellitus	0.000151	0.00268	CbGeAlD
Vandetanib—ABCG2—nephron tubule—type 2 diabetes mellitus	0.000146	0.00259	CbGeAlD
Vandetanib—PDGFRB—liver—type 2 diabetes mellitus	0.000144	0.00256	CbGeAlD
Vandetanib—ABCC1—adipose tissue—type 2 diabetes mellitus	0.000139	0.00248	CbGeAlD
Vandetanib—ORM1—liver—type 2 diabetes mellitus	0.000135	0.0024	CbGeAlD
Vandetanib—Erlotinib—ALB—type 2 diabetes mellitus	0.000134	0.0493	CrCbGaD
Vandetanib—ABL1—liver—type 2 diabetes mellitus	0.000128	0.00228	CbGeAlD
Vandetanib—ALB—liver—type 2 diabetes mellitus	0.000118	0.00211	CbGeAlD
Vandetanib—ABCG2—adipose tissue—type 2 diabetes mellitus	0.000115	0.00205	CbGeAlD
Vandetanib—ABCC1—liver—type 2 diabetes mellitus	9.77e-05	0.00174	CbGeAlD
Vandetanib—Gefitinib—CYP3A4—type 2 diabetes mellitus	9.59e-05	0.0354	CrCbGaD
Vandetanib—Bosutinib—CYP3A4—type 2 diabetes mellitus	9.44e-05	0.0348	CrCbGaD
Vandetanib—CYP3A4—kidney—type 2 diabetes mellitus	8.92e-05	0.00159	CbGeAlD
Vandetanib—Gefitinib—ALB—type 2 diabetes mellitus	8.37e-05	0.0309	CrCbGaD
Vandetanib—ABCG2—liver—type 2 diabetes mellitus	8.09e-05	0.00144	CbGeAlD
Vandetanib—Diarrhoea—Sitagliptin—type 2 diabetes mellitus	6.44e-05	0.000504	CcSEcCtD
Vandetanib—Vomiting—Glipizide—type 2 diabetes mellitus	6.43e-05	0.000504	CcSEcCtD
Vandetanib—Oedema—Valsartan—type 2 diabetes mellitus	6.42e-05	0.000503	CcSEcCtD
Vandetanib—Dizziness—Pioglitazone—type 2 diabetes mellitus	6.41e-05	0.000502	CcSEcCtD
Vandetanib—Infection—Valsartan—type 2 diabetes mellitus	6.38e-05	0.0005	CcSEcCtD
Vandetanib—Rash—Glipizide—type 2 diabetes mellitus	6.38e-05	0.000499	CcSEcCtD
Vandetanib—Vision blurred—Irbesartan—type 2 diabetes mellitus	6.37e-05	0.000499	CcSEcCtD
Vandetanib—Dermatitis—Glipizide—type 2 diabetes mellitus	6.37e-05	0.000499	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Gliclazide—type 2 diabetes mellitus	6.37e-05	0.000499	CcSEcCtD
Vandetanib—Gastrointestinal pain—Glyburide—type 2 diabetes mellitus	6.36e-05	0.000499	CcSEcCtD
Vandetanib—Oedema—Orlistat—type 2 diabetes mellitus	6.34e-05	0.000497	CcSEcCtD
Vandetanib—Headache—Glipizide—type 2 diabetes mellitus	6.33e-05	0.000496	CcSEcCtD
Vandetanib—Tremor—Irbesartan—type 2 diabetes mellitus	6.33e-05	0.000496	CcSEcCtD
Vandetanib—Insomnia—Gliclazide—type 2 diabetes mellitus	6.32e-05	0.000495	CcSEcCtD
Vandetanib—Infection—Orlistat—type 2 diabetes mellitus	6.3e-05	0.000494	CcSEcCtD
Vandetanib—Loss of consciousness—Metformin—type 2 diabetes mellitus	6.3e-05	0.000493	CcSEcCtD
Vandetanib—Nervous system disorder—Valsartan—type 2 diabetes mellitus	6.3e-05	0.000493	CcSEcCtD
Vandetanib—Thrombocytopenia—Valsartan—type 2 diabetes mellitus	6.29e-05	0.000492	CcSEcCtD
Vandetanib—Paraesthesia—Gliclazide—type 2 diabetes mellitus	6.27e-05	0.000492	CcSEcCtD
Vandetanib—Dizziness—Glimepiride—type 2 diabetes mellitus	6.24e-05	0.000489	CcSEcCtD
Vandetanib—Skin disorder—Valsartan—type 2 diabetes mellitus	6.24e-05	0.000489	CcSEcCtD
Vandetanib—Dysgeusia—Losartan—type 2 diabetes mellitus	6.23e-05	0.000488	CcSEcCtD
Vandetanib—Dyspnoea—Gliclazide—type 2 diabetes mellitus	6.23e-05	0.000488	CcSEcCtD
Vandetanib—Nervous system disorder—Orlistat—type 2 diabetes mellitus	6.22e-05	0.000487	CcSEcCtD
Vandetanib—Dizziness—Sitagliptin—type 2 diabetes mellitus	6.22e-05	0.000487	CcSEcCtD
Vandetanib—Hypertension—Metformin—type 2 diabetes mellitus	6.18e-05	0.000485	CcSEcCtD
Vandetanib—Skin disorder—Orlistat—type 2 diabetes mellitus	6.16e-05	0.000483	CcSEcCtD
Vandetanib—Abdominal pain—Glyburide—type 2 diabetes mellitus	6.15e-05	0.000482	CcSEcCtD
Vandetanib—Dyspepsia—Gliclazide—type 2 diabetes mellitus	6.15e-05	0.000482	CcSEcCtD
Vandetanib—Muscle spasms—Losartan—type 2 diabetes mellitus	6.12e-05	0.000479	CcSEcCtD
Vandetanib—Asthenia—Bromocriptine—type 2 diabetes mellitus	6.11e-05	0.000478	CcSEcCtD
Vandetanib—Chest pain—Metformin—type 2 diabetes mellitus	6.1e-05	0.000478	CcSEcCtD
Vandetanib—Headache—Pioglitazone—type 2 diabetes mellitus	6.07e-05	0.000475	CcSEcCtD
Vandetanib—Unspecified disorder of skin and subcutaneous tissue—Metformin—type 2 diabetes mellitus	6.06e-05	0.000474	CcSEcCtD
Vandetanib—Visual impairment—Ramipril—type 2 diabetes mellitus	6.04e-05	0.000473	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Gliclazide—type 2 diabetes mellitus	6.03e-05	0.000473	CcSEcCtD
Vandetanib—Fatigue—Gliclazide—type 2 diabetes mellitus	6.02e-05	0.000472	CcSEcCtD
Vandetanib—Nausea—Glipizide—type 2 diabetes mellitus	6.01e-05	0.000471	CcSEcCtD
Vandetanib—Vomiting—Glimepiride—type 2 diabetes mellitus	6e-05	0.00047	CcSEcCtD
Vandetanib—Vision blurred—Losartan—type 2 diabetes mellitus	6e-05	0.00047	CcSEcCtD
Vandetanib—Vomiting—Sitagliptin—type 2 diabetes mellitus	5.98e-05	0.000469	CcSEcCtD
Vandetanib—Constipation—Gliclazide—type 2 diabetes mellitus	5.98e-05	0.000468	CcSEcCtD
Vandetanib—Pain—Gliclazide—type 2 diabetes mellitus	5.98e-05	0.000468	CcSEcCtD
Vandetanib—Tremor—Losartan—type 2 diabetes mellitus	5.96e-05	0.000467	CcSEcCtD
Vandetanib—Rash—Glimepiride—type 2 diabetes mellitus	5.95e-05	0.000466	CcSEcCtD
Vandetanib—Dermatitis—Glimepiride—type 2 diabetes mellitus	5.94e-05	0.000466	CcSEcCtD
Vandetanib—Loss of consciousness—Irbesartan—type 2 diabetes mellitus	5.94e-05	0.000465	CcSEcCtD
Vandetanib—Rash—Sitagliptin—type 2 diabetes mellitus	5.93e-05	0.000465	CcSEcCtD
Vandetanib—Dermatitis—Sitagliptin—type 2 diabetes mellitus	5.93e-05	0.000464	CcSEcCtD
Vandetanib—Erythema multiforme—Ramipril—type 2 diabetes mellitus	5.93e-05	0.000464	CcSEcCtD
Vandetanib—Headache—Glimepiride—type 2 diabetes mellitus	5.91e-05	0.000463	CcSEcCtD
Vandetanib—Cough—Irbesartan—type 2 diabetes mellitus	5.9e-05	0.000462	CcSEcCtD
Vandetanib—Headache—Sitagliptin—type 2 diabetes mellitus	5.89e-05	0.000462	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Valsartan—type 2 diabetes mellitus	5.85e-05	0.000458	CcSEcCtD
Vandetanib—Oedema—Metformin—type 2 diabetes mellitus	5.85e-05	0.000458	CcSEcCtD
Vandetanib—Hypertension—Irbesartan—type 2 diabetes mellitus	5.84e-05	0.000457	CcSEcCtD
Vandetanib—Diarrhoea—Bromocriptine—type 2 diabetes mellitus	5.82e-05	0.000456	CcSEcCtD
Vandetanib—Infection—Metformin—type 2 diabetes mellitus	5.81e-05	0.000455	CcSEcCtD
Vandetanib—Insomnia—Valsartan—type 2 diabetes mellitus	5.81e-05	0.000455	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Orlistat—type 2 diabetes mellitus	5.78e-05	0.000453	CcSEcCtD
Vandetanib—Paraesthesia—Valsartan—type 2 diabetes mellitus	5.76e-05	0.000452	CcSEcCtD
Vandetanib—Arthralgia—Irbesartan—type 2 diabetes mellitus	5.76e-05	0.000451	CcSEcCtD
Vandetanib—Chest pain—Irbesartan—type 2 diabetes mellitus	5.76e-05	0.000451	CcSEcCtD
Vandetanib—Insomnia—Orlistat—type 2 diabetes mellitus	5.74e-05	0.00045	CcSEcCtD
Vandetanib—Anxiety—Irbesartan—type 2 diabetes mellitus	5.74e-05	0.000449	CcSEcCtD
Vandetanib—Nervous system disorder—Metformin—type 2 diabetes mellitus	5.73e-05	0.000449	CcSEcCtD
Vandetanib—Thrombocytopenia—Metformin—type 2 diabetes mellitus	5.72e-05	0.000448	CcSEcCtD
Vandetanib—Dyspnoea—Valsartan—type 2 diabetes mellitus	5.72e-05	0.000448	CcSEcCtD
Vandetanib—Unspecified disorder of skin and subcutaneous tissue—Irbesartan—type 2 diabetes mellitus	5.72e-05	0.000448	CcSEcCtD
Vandetanib—Gastrointestinal pain—Gliclazide—type 2 diabetes mellitus	5.71e-05	0.000448	CcSEcCtD
Vandetanib—Paraesthesia—Orlistat—type 2 diabetes mellitus	5.7e-05	0.000446	CcSEcCtD
Vandetanib—Skin disorder—Metformin—type 2 diabetes mellitus	5.68e-05	0.000445	CcSEcCtD
Vandetanib—Dyspepsia—Valsartan—type 2 diabetes mellitus	5.65e-05	0.000443	CcSEcCtD
Vandetanib—Mediastinal disorder—Ramipril—type 2 diabetes mellitus	5.65e-05	0.000442	CcSEcCtD
Vandetanib—CYP3A4—liver—type 2 diabetes mellitus	5.64e-05	0.001	CbGeAlD
Vandetanib—Dizziness—Bromocriptine—type 2 diabetes mellitus	5.63e-05	0.000441	CcSEcCtD
Vandetanib—Dry mouth—Irbesartan—type 2 diabetes mellitus	5.63e-05	0.000441	CcSEcCtD
Vandetanib—Nausea—Glimepiride—type 2 diabetes mellitus	5.6e-05	0.000439	CcSEcCtD
Vandetanib—Arrhythmia—Ramipril—type 2 diabetes mellitus	5.6e-05	0.000439	CcSEcCtD
Vandetanib—Loss of consciousness—Losartan—type 2 diabetes mellitus	5.59e-05	0.000438	CcSEcCtD
Vandetanib—Nausea—Sitagliptin—type 2 diabetes mellitus	5.59e-05	0.000438	CcSEcCtD
Vandetanib—Dyspepsia—Orlistat—type 2 diabetes mellitus	5.58e-05	0.000437	CcSEcCtD
Vandetanib—Asthenia—Glyburide—type 2 diabetes mellitus	5.58e-05	0.000437	CcSEcCtD
Vandetanib—Decreased appetite—Valsartan—type 2 diabetes mellitus	5.58e-05	0.000437	CcSEcCtD
Vandetanib—Cough—Losartan—type 2 diabetes mellitus	5.55e-05	0.000435	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Valsartan—type 2 diabetes mellitus	5.54e-05	0.000434	CcSEcCtD
Vandetanib—Alopecia—Ramipril—type 2 diabetes mellitus	5.54e-05	0.000434	CcSEcCtD
Vandetanib—Fatigue—Valsartan—type 2 diabetes mellitus	5.54e-05	0.000434	CcSEcCtD
Vandetanib—Abdominal pain—Gliclazide—type 2 diabetes mellitus	5.52e-05	0.000433	CcSEcCtD
Vandetanib—Body temperature increased—Gliclazide—type 2 diabetes mellitus	5.52e-05	0.000433	CcSEcCtD
Vandetanib—Oedema—Irbesartan—type 2 diabetes mellitus	5.52e-05	0.000432	CcSEcCtD
Vandetanib—Decreased appetite—Orlistat—type 2 diabetes mellitus	5.51e-05	0.000432	CcSEcCtD
Vandetanib—Pruritus—Glyburide—type 2 diabetes mellitus	5.51e-05	0.000431	CcSEcCtD
Vandetanib—Mental disorder—Ramipril—type 2 diabetes mellitus	5.49e-05	0.00043	CcSEcCtD
Vandetanib—Constipation—Valsartan—type 2 diabetes mellitus	5.49e-05	0.00043	CcSEcCtD
Vandetanib—Infection—Irbesartan—type 2 diabetes mellitus	5.48e-05	0.000429	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Orlistat—type 2 diabetes mellitus	5.48e-05	0.000429	CcSEcCtD
Vandetanib—Fatigue—Orlistat—type 2 diabetes mellitus	5.47e-05	0.000428	CcSEcCtD
Vandetanib—Malnutrition—Ramipril—type 2 diabetes mellitus	5.46e-05	0.000427	CcSEcCtD
Vandetanib—Pain—Orlistat—type 2 diabetes mellitus	5.42e-05	0.000425	CcSEcCtD
Vandetanib—Chest pain—Losartan—type 2 diabetes mellitus	5.42e-05	0.000424	CcSEcCtD
Vandetanib—Arthralgia—Losartan—type 2 diabetes mellitus	5.42e-05	0.000424	CcSEcCtD
Vandetanib—Vomiting—Bromocriptine—type 2 diabetes mellitus	5.41e-05	0.000424	CcSEcCtD
Vandetanib—Nervous system disorder—Irbesartan—type 2 diabetes mellitus	5.41e-05	0.000424	CcSEcCtD
Vandetanib—Thrombocytopenia—Irbesartan—type 2 diabetes mellitus	5.4e-05	0.000423	CcSEcCtD
Vandetanib—Anxiety—Losartan—type 2 diabetes mellitus	5.4e-05	0.000423	CcSEcCtD
Vandetanib—Rash—Bromocriptine—type 2 diabetes mellitus	5.37e-05	0.00042	CcSEcCtD
Vandetanib—Dermatitis—Bromocriptine—type 2 diabetes mellitus	5.36e-05	0.00042	CcSEcCtD
Vandetanib—Skin disorder—Irbesartan—type 2 diabetes mellitus	5.36e-05	0.00042	CcSEcCtD
Vandetanib—Dysgeusia—Ramipril—type 2 diabetes mellitus	5.34e-05	0.000419	CcSEcCtD
Vandetanib—Headache—Bromocriptine—type 2 diabetes mellitus	5.33e-05	0.000418	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Metformin—type 2 diabetes mellitus	5.33e-05	0.000417	CcSEcCtD
Vandetanib—Diarrhoea—Glyburide—type 2 diabetes mellitus	5.32e-05	0.000417	CcSEcCtD
Vandetanib—Dry mouth—Losartan—type 2 diabetes mellitus	5.3e-05	0.000415	CcSEcCtD
Vandetanib—Gastrointestinal pain—Valsartan—type 2 diabetes mellitus	5.25e-05	0.000411	CcSEcCtD
Vandetanib—Paraesthesia—Metformin—type 2 diabetes mellitus	5.25e-05	0.000411	CcSEcCtD
Vandetanib—Muscle spasms—Ramipril—type 2 diabetes mellitus	5.24e-05	0.000411	CcSEcCtD
Vandetanib—Dyspnoea—Metformin—type 2 diabetes mellitus	5.21e-05	0.000408	CcSEcCtD
Vandetanib—Oedema—Losartan—type 2 diabetes mellitus	5.19e-05	0.000407	CcSEcCtD
Vandetanib—Gastrointestinal pain—Orlistat—type 2 diabetes mellitus	5.19e-05	0.000406	CcSEcCtD
Vandetanib—Infection—Losartan—type 2 diabetes mellitus	5.16e-05	0.000404	CcSEcCtD
Vandetanib—Dyspepsia—Metformin—type 2 diabetes mellitus	5.15e-05	0.000403	CcSEcCtD
Vandetanib—Tremor—Ramipril—type 2 diabetes mellitus	5.11e-05	0.0004	CcSEcCtD
Vandetanib—Nervous system disorder—Losartan—type 2 diabetes mellitus	5.09e-05	0.000399	CcSEcCtD
Vandetanib—Thrombocytopenia—Losartan—type 2 diabetes mellitus	5.08e-05	0.000398	CcSEcCtD
Vandetanib—Decreased appetite—Metformin—type 2 diabetes mellitus	5.08e-05	0.000398	CcSEcCtD
Vandetanib—Abdominal pain—Valsartan—type 2 diabetes mellitus	5.08e-05	0.000398	CcSEcCtD
Vandetanib—Nausea—Bromocriptine—type 2 diabetes mellitus	5.06e-05	0.000396	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Metformin—type 2 diabetes mellitus	5.05e-05	0.000395	CcSEcCtD
Vandetanib—Fatigue—Metformin—type 2 diabetes mellitus	5.04e-05	0.000395	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Irbesartan—type 2 diabetes mellitus	5.03e-05	0.000394	CcSEcCtD
Vandetanib—Abdominal pain—Orlistat—type 2 diabetes mellitus	5.01e-05	0.000393	CcSEcCtD
Vandetanib—Body temperature increased—Orlistat—type 2 diabetes mellitus	5.01e-05	0.000393	CcSEcCtD
Vandetanib—Asthenia—Gliclazide—type 2 diabetes mellitus	5.01e-05	0.000393	CcSEcCtD
Vandetanib—Constipation—Metformin—type 2 diabetes mellitus	5e-05	0.000392	CcSEcCtD
Vandetanib—Paraesthesia—Irbesartan—type 2 diabetes mellitus	4.95e-05	0.000388	CcSEcCtD
Vandetanib—Vomiting—Glyburide—type 2 diabetes mellitus	4.95e-05	0.000388	CcSEcCtD
Vandetanib—Pruritus—Gliclazide—type 2 diabetes mellitus	4.94e-05	0.000387	CcSEcCtD
Vandetanib—Dyspnoea—Irbesartan—type 2 diabetes mellitus	4.92e-05	0.000385	CcSEcCtD
Vandetanib—Rash—Glyburide—type 2 diabetes mellitus	4.91e-05	0.000384	CcSEcCtD
Vandetanib—Dermatitis—Glyburide—type 2 diabetes mellitus	4.9e-05	0.000384	CcSEcCtD
Vandetanib—Headache—Glyburide—type 2 diabetes mellitus	4.88e-05	0.000382	CcSEcCtD
Vandetanib—Dyspepsia—Irbesartan—type 2 diabetes mellitus	4.86e-05	0.00038	CcSEcCtD
Vandetanib—Decreased appetite—Irbesartan—type 2 diabetes mellitus	4.8e-05	0.000376	CcSEcCtD
Vandetanib—Loss of consciousness—Ramipril—type 2 diabetes mellitus	4.79e-05	0.000376	CcSEcCtD
Vandetanib—Diarrhoea—Gliclazide—type 2 diabetes mellitus	4.78e-05	0.000375	CcSEcCtD
Vandetanib—Gastrointestinal pain—Metformin—type 2 diabetes mellitus	4.78e-05	0.000375	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Irbesartan—type 2 diabetes mellitus	4.76e-05	0.000373	CcSEcCtD
Vandetanib—Cough—Ramipril—type 2 diabetes mellitus	4.76e-05	0.000373	CcSEcCtD
Vandetanib—Fatigue—Irbesartan—type 2 diabetes mellitus	4.76e-05	0.000373	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Losartan—type 2 diabetes mellitus	4.73e-05	0.000371	CcSEcCtD
Vandetanib—Convulsion—Ramipril—type 2 diabetes mellitus	4.73e-05	0.00037	CcSEcCtD
Vandetanib—Pain—Irbesartan—type 2 diabetes mellitus	4.72e-05	0.00037	CcSEcCtD
Vandetanib—Constipation—Irbesartan—type 2 diabetes mellitus	4.72e-05	0.00037	CcSEcCtD
Vandetanib—Insomnia—Losartan—type 2 diabetes mellitus	4.7e-05	0.000368	CcSEcCtD
Vandetanib—Paraesthesia—Losartan—type 2 diabetes mellitus	4.66e-05	0.000365	CcSEcCtD
Vandetanib—Arthralgia—Ramipril—type 2 diabetes mellitus	4.64e-05	0.000364	CcSEcCtD
Vandetanib—Chest pain—Ramipril—type 2 diabetes mellitus	4.64e-05	0.000364	CcSEcCtD
Vandetanib—Dyspnoea—Losartan—type 2 diabetes mellitus	4.63e-05	0.000363	CcSEcCtD
Vandetanib—Anxiety—Ramipril—type 2 diabetes mellitus	4.63e-05	0.000363	CcSEcCtD
Vandetanib—Nausea—Glyburide—type 2 diabetes mellitus	4.62e-05	0.000362	CcSEcCtD
Vandetanib—Abdominal pain—Metformin—type 2 diabetes mellitus	4.62e-05	0.000362	CcSEcCtD
Vandetanib—Dizziness—Gliclazide—type 2 diabetes mellitus	4.62e-05	0.000362	CcSEcCtD
Vandetanib—Unspecified disorder of skin and subcutaneous tissue—Ramipril—type 2 diabetes mellitus	4.61e-05	0.000361	CcSEcCtD
Vandetanib—Asthenia—Valsartan—type 2 diabetes mellitus	4.61e-05	0.000361	CcSEcCtD
Vandetanib—Dyspepsia—Losartan—type 2 diabetes mellitus	4.57e-05	0.000358	CcSEcCtD
Vandetanib—Asthenia—Orlistat—type 2 diabetes mellitus	4.55e-05	0.000357	CcSEcCtD
Vandetanib—Pruritus—Valsartan—type 2 diabetes mellitus	4.54e-05	0.000356	CcSEcCtD
Vandetanib—Dry mouth—Ramipril—type 2 diabetes mellitus	4.54e-05	0.000356	CcSEcCtD
Vandetanib—Decreased appetite—Losartan—type 2 diabetes mellitus	4.51e-05	0.000354	CcSEcCtD
Vandetanib—Gastrointestinal pain—Irbesartan—type 2 diabetes mellitus	4.51e-05	0.000353	CcSEcCtD
Vandetanib—Pruritus—Orlistat—type 2 diabetes mellitus	4.49e-05	0.000352	CcSEcCtD
Vandetanib—Fatigue—Losartan—type 2 diabetes mellitus	4.48e-05	0.000351	CcSEcCtD
Vandetanib—Oedema—Ramipril—type 2 diabetes mellitus	4.45e-05	0.000349	CcSEcCtD
Vandetanib—Vomiting—Gliclazide—type 2 diabetes mellitus	4.44e-05	0.000348	CcSEcCtD
Vandetanib—Pain—Losartan—type 2 diabetes mellitus	4.44e-05	0.000348	CcSEcCtD
Vandetanib—Constipation—Losartan—type 2 diabetes mellitus	4.44e-05	0.000348	CcSEcCtD
Vandetanib—Rash—Gliclazide—type 2 diabetes mellitus	4.41e-05	0.000345	CcSEcCtD
Vandetanib—Dermatitis—Gliclazide—type 2 diabetes mellitus	4.4e-05	0.000345	CcSEcCtD
Vandetanib—Diarrhoea—Valsartan—type 2 diabetes mellitus	4.39e-05	0.000344	CcSEcCtD
Vandetanib—Headache—Gliclazide—type 2 diabetes mellitus	4.38e-05	0.000343	CcSEcCtD
Vandetanib—Nervous system disorder—Ramipril—type 2 diabetes mellitus	4.37e-05	0.000342	CcSEcCtD
Vandetanib—Body temperature increased—Irbesartan—type 2 diabetes mellitus	4.36e-05	0.000342	CcSEcCtD
Vandetanib—Abdominal pain—Irbesartan—type 2 diabetes mellitus	4.36e-05	0.000342	CcSEcCtD
Vandetanib—Thrombocytopenia—Ramipril—type 2 diabetes mellitus	4.36e-05	0.000342	CcSEcCtD
Vandetanib—Diarrhoea—Orlistat—type 2 diabetes mellitus	4.34e-05	0.00034	CcSEcCtD
Vandetanib—Skin disorder—Ramipril—type 2 diabetes mellitus	4.32e-05	0.000339	CcSEcCtD
Vandetanib—Gastrointestinal pain—Losartan—type 2 diabetes mellitus	4.25e-05	0.000333	CcSEcCtD
Vandetanib—Dizziness—Valsartan—type 2 diabetes mellitus	4.25e-05	0.000333	CcSEcCtD
Vandetanib—Dizziness—Orlistat—type 2 diabetes mellitus	4.2e-05	0.000329	CcSEcCtD
Vandetanib—Asthenia—Metformin—type 2 diabetes mellitus	4.19e-05	0.000329	CcSEcCtD
Vandetanib—Nausea—Gliclazide—type 2 diabetes mellitus	4.15e-05	0.000325	CcSEcCtD
Vandetanib—Pruritus—Metformin—type 2 diabetes mellitus	4.14e-05	0.000324	CcSEcCtD
Vandetanib—Abdominal pain—Losartan—type 2 diabetes mellitus	4.1e-05	0.000322	CcSEcCtD
Vandetanib—Body temperature increased—Losartan—type 2 diabetes mellitus	4.1e-05	0.000322	CcSEcCtD
Vandetanib—Vomiting—Valsartan—type 2 diabetes mellitus	4.08e-05	0.00032	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Ramipril—type 2 diabetes mellitus	4.06e-05	0.000318	CcSEcCtD
Vandetanib—Rash—Valsartan—type 2 diabetes mellitus	4.05e-05	0.000317	CcSEcCtD
Vandetanib—Dermatitis—Valsartan—type 2 diabetes mellitus	4.04e-05	0.000317	CcSEcCtD
Vandetanib—Vomiting—Orlistat—type 2 diabetes mellitus	4.03e-05	0.000316	CcSEcCtD
Vandetanib—Insomnia—Ramipril—type 2 diabetes mellitus	4.03e-05	0.000315	CcSEcCtD
Vandetanib—Headache—Valsartan—type 2 diabetes mellitus	4.02e-05	0.000315	CcSEcCtD
Vandetanib—Diarrhoea—Metformin—type 2 diabetes mellitus	4e-05	0.000313	CcSEcCtD
Vandetanib—Rash—Orlistat—type 2 diabetes mellitus	4e-05	0.000313	CcSEcCtD
Vandetanib—Paraesthesia—Ramipril—type 2 diabetes mellitus	4e-05	0.000313	CcSEcCtD
Vandetanib—Dermatitis—Orlistat—type 2 diabetes mellitus	4e-05	0.000313	CcSEcCtD
Vandetanib—Headache—Orlistat—type 2 diabetes mellitus	3.97e-05	0.000311	CcSEcCtD
Vandetanib—Dyspnoea—Ramipril—type 2 diabetes mellitus	3.97e-05	0.000311	CcSEcCtD
Vandetanib—Asthenia—Irbesartan—type 2 diabetes mellitus	3.96e-05	0.00031	CcSEcCtD
Vandetanib—Dyspepsia—Ramipril—type 2 diabetes mellitus	3.92e-05	0.000307	CcSEcCtD
Vandetanib—Pruritus—Irbesartan—type 2 diabetes mellitus	3.9e-05	0.000306	CcSEcCtD
Vandetanib—Decreased appetite—Ramipril—type 2 diabetes mellitus	3.87e-05	0.000303	CcSEcCtD
Vandetanib—Dizziness—Metformin—type 2 diabetes mellitus	3.87e-05	0.000303	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Ramipril—type 2 diabetes mellitus	3.84e-05	0.000301	CcSEcCtD
Vandetanib—Fatigue—Ramipril—type 2 diabetes mellitus	3.84e-05	0.000301	CcSEcCtD
Vandetanib—Nausea—Valsartan—type 2 diabetes mellitus	3.81e-05	0.000299	CcSEcCtD
Vandetanib—Constipation—Ramipril—type 2 diabetes mellitus	3.81e-05	0.000298	CcSEcCtD
Vandetanib—Diarrhoea—Irbesartan—type 2 diabetes mellitus	3.77e-05	0.000296	CcSEcCtD
Vandetanib—Nausea—Orlistat—type 2 diabetes mellitus	3.77e-05	0.000295	CcSEcCtD
Vandetanib—Asthenia—Losartan—type 2 diabetes mellitus	3.73e-05	0.000292	CcSEcCtD
Vandetanib—Vomiting—Metformin—type 2 diabetes mellitus	3.72e-05	0.000291	CcSEcCtD
Vandetanib—Rash—Metformin—type 2 diabetes mellitus	3.69e-05	0.000289	CcSEcCtD
Vandetanib—Dermatitis—Metformin—type 2 diabetes mellitus	3.68e-05	0.000289	CcSEcCtD
Vandetanib—Pruritus—Losartan—type 2 diabetes mellitus	3.67e-05	0.000288	CcSEcCtD
Vandetanib—Headache—Metformin—type 2 diabetes mellitus	3.66e-05	0.000287	CcSEcCtD
Vandetanib—Dizziness—Irbesartan—type 2 diabetes mellitus	3.65e-05	0.000286	CcSEcCtD
Vandetanib—Gastrointestinal pain—Ramipril—type 2 diabetes mellitus	3.64e-05	0.000285	CcSEcCtD
Vandetanib—Diarrhoea—Losartan—type 2 diabetes mellitus	3.55e-05	0.000278	CcSEcCtD
Vandetanib—Abdominal pain—Ramipril—type 2 diabetes mellitus	3.52e-05	0.000276	CcSEcCtD
Vandetanib—Body temperature increased—Ramipril—type 2 diabetes mellitus	3.52e-05	0.000276	CcSEcCtD
Vandetanib—Vomiting—Irbesartan—type 2 diabetes mellitus	3.51e-05	0.000275	CcSEcCtD
Vandetanib—Rash—Irbesartan—type 2 diabetes mellitus	3.48e-05	0.000273	CcSEcCtD
Vandetanib—Dermatitis—Irbesartan—type 2 diabetes mellitus	3.48e-05	0.000272	CcSEcCtD
Vandetanib—Nausea—Metformin—type 2 diabetes mellitus	3.47e-05	0.000272	CcSEcCtD
Vandetanib—Headache—Irbesartan—type 2 diabetes mellitus	3.46e-05	0.000271	CcSEcCtD
Vandetanib—Dizziness—Losartan—type 2 diabetes mellitus	3.43e-05	0.000269	CcSEcCtD
Vandetanib—Vomiting—Losartan—type 2 diabetes mellitus	3.3e-05	0.000259	CcSEcCtD
Vandetanib—Nausea—Irbesartan—type 2 diabetes mellitus	3.28e-05	0.000257	CcSEcCtD
Vandetanib—Rash—Losartan—type 2 diabetes mellitus	3.27e-05	0.000256	CcSEcCtD
Vandetanib—Dermatitis—Losartan—type 2 diabetes mellitus	3.27e-05	0.000256	CcSEcCtD
Vandetanib—Headache—Losartan—type 2 diabetes mellitus	3.25e-05	0.000255	CcSEcCtD
Vandetanib—Asthenia—Ramipril—type 2 diabetes mellitus	3.19e-05	0.00025	CcSEcCtD
Vandetanib—Pruritus—Ramipril—type 2 diabetes mellitus	3.15e-05	0.000247	CcSEcCtD
Vandetanib—Nausea—Losartan—type 2 diabetes mellitus	3.08e-05	0.000242	CcSEcCtD
Vandetanib—Diarrhoea—Ramipril—type 2 diabetes mellitus	3.05e-05	0.000239	CcSEcCtD
Vandetanib—Dizziness—Ramipril—type 2 diabetes mellitus	2.94e-05	0.000231	CcSEcCtD
Vandetanib—Vomiting—Ramipril—type 2 diabetes mellitus	2.83e-05	0.000222	CcSEcCtD
Vandetanib—Rash—Ramipril—type 2 diabetes mellitus	2.81e-05	0.00022	CcSEcCtD
Vandetanib—Dermatitis—Ramipril—type 2 diabetes mellitus	2.8e-05	0.00022	CcSEcCtD
Vandetanib—Headache—Ramipril—type 2 diabetes mellitus	2.79e-05	0.000219	CcSEcCtD
Vandetanib—Nausea—Ramipril—type 2 diabetes mellitus	2.64e-05	0.000207	CcSEcCtD
Vandetanib—LCK—Immune System—NFKB1—type 2 diabetes mellitus	9.6e-07	8.26e-06	CbGpPWpGaD
Vandetanib—SRC—Developmental Biology—AKT1—type 2 diabetes mellitus	9.57e-07	8.23e-06	CbGpPWpGaD
Vandetanib—ERBB3—Disease—AKT1—type 2 diabetes mellitus	9.57e-07	8.23e-06	CbGpPWpGaD
Vandetanib—LYN—Immune System—EGFR—type 2 diabetes mellitus	9.57e-07	8.23e-06	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—EGFR—type 2 diabetes mellitus	9.55e-07	8.22e-06	CbGpPWpGaD
Vandetanib—LCK—Innate Immune System—AKT1—type 2 diabetes mellitus	9.54e-07	8.21e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—NOS3—type 2 diabetes mellitus	9.54e-07	8.21e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	9.54e-07	8.21e-06	CbGpPWpGaD
Vandetanib—ABL1—Immune System—EGFR—type 2 diabetes mellitus	9.52e-07	8.19e-06	CbGpPWpGaD
Vandetanib—EGFR—Adaptive Immune System—AKT1—type 2 diabetes mellitus	9.51e-07	8.18e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—ALDOB—type 2 diabetes mellitus	9.5e-07	8.18e-06	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—ALB—type 2 diabetes mellitus	9.47e-07	8.15e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—HIF1A—type 2 diabetes mellitus	9.46e-07	8.14e-06	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—SRC—type 2 diabetes mellitus	9.46e-07	8.14e-06	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—EGFR—type 2 diabetes mellitus	9.45e-07	8.13e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—IRS2—type 2 diabetes mellitus	9.44e-07	8.12e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—AGT—type 2 diabetes mellitus	9.43e-07	8.11e-06	CbGpPWpGaD
Vandetanib—FYN—Immune System—EGFR—type 2 diabetes mellitus	9.42e-07	8.1e-06	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—PTGS2—type 2 diabetes mellitus	9.41e-07	8.1e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—NOS3—type 2 diabetes mellitus	9.39e-07	8.08e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	9.39e-07	8.08e-06	CbGpPWpGaD
Vandetanib—SRC—Hemostasis—AKT1—type 2 diabetes mellitus	9.38e-07	8.08e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—APOB—type 2 diabetes mellitus	9.32e-07	8.02e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—IRS1—type 2 diabetes mellitus	9.31e-07	8.01e-06	CbGpPWpGaD
Vandetanib—EGFR—Immune System—SRC—type 2 diabetes mellitus	9.28e-07	7.99e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—CALM1—type 2 diabetes mellitus	9.27e-07	7.98e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—INS—type 2 diabetes mellitus	9.25e-07	7.96e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—APOE—type 2 diabetes mellitus	9.24e-07	7.95e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—LEP—type 2 diabetes mellitus	9.24e-07	7.95e-06	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—VEGFA—type 2 diabetes mellitus	9.22e-07	7.93e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—TGFB1—type 2 diabetes mellitus	9.2e-07	7.92e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—RELA—type 2 diabetes mellitus	9.17e-07	7.89e-06	CbGpPWpGaD
Vandetanib—LCK—Adaptive Immune System—AKT1—type 2 diabetes mellitus	9.16e-07	7.89e-06	CbGpPWpGaD
Vandetanib—SRC—Innate Immune System—IL6—type 2 diabetes mellitus	9.16e-07	7.88e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—APOA1—type 2 diabetes mellitus	9.13e-07	7.86e-06	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—TGFB1—type 2 diabetes mellitus	9.12e-07	7.84e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—CCL2—type 2 diabetes mellitus	9.1e-07	7.83e-06	CbGpPWpGaD
Vandetanib—YES1—Immune System—AKT1—type 2 diabetes mellitus	9.1e-07	7.83e-06	CbGpPWpGaD
Vandetanib—ABCC1—Disease—SRC—type 2 diabetes mellitus	9.09e-07	7.82e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—GSTM1—type 2 diabetes mellitus	9.07e-07	7.8e-06	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—PIK3R1—type 2 diabetes mellitus	9.06e-07	7.79e-06	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—NOS3—type 2 diabetes mellitus	9.06e-07	7.79e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—PTGS2—type 2 diabetes mellitus	9.04e-07	7.78e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—EGFR—type 2 diabetes mellitus	9.02e-07	7.76e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—RELA—type 2 diabetes mellitus	8.98e-07	7.73e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—IGF1—type 2 diabetes mellitus	8.95e-07	7.7e-06	CbGpPWpGaD
Vandetanib—LCK—Immune System—SRC—type 2 diabetes mellitus	8.94e-07	7.7e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—AKT2—type 2 diabetes mellitus	8.94e-07	7.69e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—INS—type 2 diabetes mellitus	8.92e-07	7.67e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—LPL—type 2 diabetes mellitus	8.9e-07	7.66e-06	CbGpPWpGaD
Vandetanib—FYN—Disease—TGFB1—type 2 diabetes mellitus	8.87e-07	7.63e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—RELA—type 2 diabetes mellitus	8.84e-07	7.61e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—GLP1R—type 2 diabetes mellitus	8.83e-07	7.6e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—CCL2—type 2 diabetes mellitus	8.77e-07	7.55e-06	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—TGFB1—type 2 diabetes mellitus	8.76e-07	7.53e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—ADCY5—type 2 diabetes mellitus	8.71e-07	7.5e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—PRKCB—type 2 diabetes mellitus	8.71e-07	7.5e-06	CbGpPWpGaD
Vandetanib—FYN—Disease—EGFR—type 2 diabetes mellitus	8.69e-07	7.48e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—GPX1—type 2 diabetes mellitus	8.68e-07	7.47e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—IGF1—type 2 diabetes mellitus	8.62e-07	7.42e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—AKT2—type 2 diabetes mellitus	8.62e-07	7.41e-06	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—EGFR—type 2 diabetes mellitus	8.59e-07	7.39e-06	CbGpPWpGaD
Vandetanib—EGFR—Disease—SRC—type 2 diabetes mellitus	8.57e-07	7.37e-06	CbGpPWpGaD
Vandetanib—SRC—Immune System—NFKB1—type 2 diabetes mellitus	8.5e-07	7.31e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	8.5e-07	7.31e-06	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—TGFB1—type 2 diabetes mellitus	8.46e-07	7.28e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—CD36—type 2 diabetes mellitus	8.46e-07	7.28e-06	CbGpPWpGaD
Vandetanib—SRC—Innate Immune System—AKT1—type 2 diabetes mellitus	8.45e-07	7.27e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—PPP2CA—type 2 diabetes mellitus	8.35e-07	7.19e-06	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—EGFR—type 2 diabetes mellitus	8.29e-07	7.14e-06	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—PTGS2—type 2 diabetes mellitus	8.28e-07	7.13e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—CASP3—type 2 diabetes mellitus	8.27e-07	7.12e-06	CbGpPWpGaD
Vandetanib—LCK—Disease—SRC—type 2 diabetes mellitus	8.26e-07	7.11e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—SLC2A2—type 2 diabetes mellitus	8.25e-07	7.1e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—IRS1—type 2 diabetes mellitus	8.24e-07	7.09e-06	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—IL6—type 2 diabetes mellitus	8.24e-07	7.09e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	8.19e-07	7.05e-06	CbGpPWpGaD
Vandetanib—ABCC1—Disease—TGFB1—type 2 diabetes mellitus	8.13e-07	6.99e-06	CbGpPWpGaD
Vandetanib—SRC—Adaptive Immune System—AKT1—type 2 diabetes mellitus	8.11e-07	6.98e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—NOS3—type 2 diabetes mellitus	8.11e-07	6.98e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	8.11e-07	6.98e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—CASP3—type 2 diabetes mellitus	8.1e-07	6.97e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—CPT1A—type 2 diabetes mellitus	8.08e-07	6.95e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—MTR—type 2 diabetes mellitus	8.08e-07	6.95e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—MTHFR—type 2 diabetes mellitus	8.01e-07	6.9e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—CASP3—type 2 diabetes mellitus	7.97e-07	6.86e-06	CbGpPWpGaD
Vandetanib—ABCC1—Disease—EGFR—type 2 diabetes mellitus	7.97e-07	6.86e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—NAMPT—type 2 diabetes mellitus	7.92e-07	6.82e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—INS—type 2 diabetes mellitus	7.89e-07	6.79e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—GCK—type 2 diabetes mellitus	7.87e-07	6.77e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—HBA1—type 2 diabetes mellitus	7.87e-07	6.77e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—LIPC—type 2 diabetes mellitus	7.87e-07	6.77e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—PPARA—type 2 diabetes mellitus	7.86e-07	6.76e-06	CbGpPWpGaD
Vandetanib—LCK—Immune System—EGFR—type 2 diabetes mellitus	7.84e-07	6.75e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—CYP11A1—type 2 diabetes mellitus	7.82e-07	6.73e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—NOS3—type 2 diabetes mellitus	7.82e-07	6.73e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	7.82e-07	6.73e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—MMP9—type 2 diabetes mellitus	7.82e-07	6.73e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—CCL2—type 2 diabetes mellitus	7.77e-07	6.68e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—NFKB1—type 2 diabetes mellitus	7.73e-07	6.65e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—SLC9A1—type 2 diabetes mellitus	7.68e-07	6.61e-06	CbGpPWpGaD
Vandetanib—EGFR—Disease—TGFB1—type 2 diabetes mellitus	7.66e-07	6.59e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—MMP9—type 2 diabetes mellitus	7.65e-07	6.58e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—RELA—type 2 diabetes mellitus	7.64e-07	6.57e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—IGF1—type 2 diabetes mellitus	7.63e-07	6.57e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—AKT2—type 2 diabetes mellitus	7.63e-07	6.56e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—AGT—type 2 diabetes mellitus	7.61e-07	6.55e-06	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—AKT1—type 2 diabetes mellitus	7.6e-07	6.54e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—CETP—type 2 diabetes mellitus	7.6e-07	6.54e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—NFKB1—type 2 diabetes mellitus	7.57e-07	6.51e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—MMP9—type 2 diabetes mellitus	7.53e-07	6.48e-06	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—IL6—type 2 diabetes mellitus	7.53e-07	6.48e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—IL6—type 2 diabetes mellitus	7.51e-07	6.46e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—CALM1—type 2 diabetes mellitus	7.49e-07	6.44e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—APOE—type 2 diabetes mellitus	7.46e-07	6.42e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—NFKB1—type 2 diabetes mellitus	7.45e-07	6.41e-06	CbGpPWpGaD
Vandetanib—LCK—Disease—TGFB1—type 2 diabetes mellitus	7.38e-07	6.35e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—APOA1—type 2 diabetes mellitus	7.38e-07	6.35e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—RELA—type 2 diabetes mellitus	7.36e-07	6.33e-06	CbGpPWpGaD
Vandetanib—LYN—Immune System—IL6—type 2 diabetes mellitus	7.35e-07	6.33e-06	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—IL6—type 2 diabetes mellitus	7.34e-07	6.32e-06	CbGpPWpGaD
Vandetanib—ABL1—Immune System—IL6—type 2 diabetes mellitus	7.32e-07	6.3e-06	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—IL6—type 2 diabetes mellitus	7.26e-07	6.25e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	7.25e-07	6.24e-06	CbGpPWpGaD
Vandetanib—LCK—Disease—EGFR—type 2 diabetes mellitus	7.24e-07	6.23e-06	CbGpPWpGaD
Vandetanib—FYN—Immune System—IL6—type 2 diabetes mellitus	7.24e-07	6.23e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—SRC—type 2 diabetes mellitus	7.21e-07	6.2e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—SREBF1—type 2 diabetes mellitus	7.06e-07	6.08e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—SNAP25—type 2 diabetes mellitus	7.06e-07	6.08e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PSMD6—type 2 diabetes mellitus	7.06e-07	6.08e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—SRC—type 2 diabetes mellitus	7.06e-07	6.07e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—VEGFA—type 2 diabetes mellitus	7.02e-07	6.04e-06	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—AKT1—type 2 diabetes mellitus	6.95e-07	5.98e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—SRC—type 2 diabetes mellitus	6.95e-07	5.98e-06	CbGpPWpGaD
Vandetanib—SRC—Immune System—EGFR—type 2 diabetes mellitus	6.94e-07	5.97e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—IL6—type 2 diabetes mellitus	6.93e-07	5.96e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—CTGF—type 2 diabetes mellitus	6.93e-07	5.96e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—AKT1—type 2 diabetes mellitus	6.93e-07	5.96e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	6.92e-07	5.96e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—NOS3—type 2 diabetes mellitus	6.92e-07	5.96e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—CASP3—type 2 diabetes mellitus	6.89e-07	5.93e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—VEGFA—type 2 diabetes mellitus	6.87e-07	5.91e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—HMGCR—type 2 diabetes mellitus	6.87e-07	5.91e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—IL6—type 2 diabetes mellitus	6.84e-07	5.89e-06	CbGpPWpGaD
Vandetanib—LYN—Immune System—AKT1—type 2 diabetes mellitus	6.78e-07	5.84e-06	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—AKT1—type 2 diabetes mellitus	6.77e-07	5.83e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—VEGFA—type 2 diabetes mellitus	6.77e-07	5.82e-06	CbGpPWpGaD
Vandetanib—ABL1—Immune System—AKT1—type 2 diabetes mellitus	6.75e-07	5.81e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—ADRA2A—type 2 diabetes mellitus	6.72e-07	5.78e-06	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—AKT1—type 2 diabetes mellitus	6.7e-07	5.76e-06	CbGpPWpGaD
Vandetanib—FYN—Disease—IL6—type 2 diabetes mellitus	6.68e-07	5.75e-06	CbGpPWpGaD
Vandetanib—FYN—Immune System—AKT1—type 2 diabetes mellitus	6.68e-07	5.74e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—CASP3—type 2 diabetes mellitus	6.64e-07	5.71e-06	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—IL6—type 2 diabetes mellitus	6.6e-07	5.68e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—TGFB1—type 2 diabetes mellitus	6.54e-07	5.62e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—RELA—type 2 diabetes mellitus	6.51e-07	5.61e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—MMP9—type 2 diabetes mellitus	6.51e-07	5.6e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—PPARG—type 2 diabetes mellitus	6.5e-07	5.59e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—CYP2E1—type 2 diabetes mellitus	6.46e-07	5.56e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—TGFB1—type 2 diabetes mellitus	6.44e-07	5.54e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—NFKB1—type 2 diabetes mellitus	6.44e-07	5.54e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—EGFR—type 2 diabetes mellitus	6.41e-07	5.51e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—AKT1—type 2 diabetes mellitus	6.4e-07	5.5e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—CYP1A2—type 2 diabetes mellitus	6.39e-07	5.5e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—SLC2A1—type 2 diabetes mellitus	6.39e-07	5.5e-06	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—IL6—type 2 diabetes mellitus	6.37e-07	5.48e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—INS—type 2 diabetes mellitus	6.37e-07	5.48e-06	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—AKT1—type 2 diabetes mellitus	6.34e-07	5.45e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—EGFR—type 2 diabetes mellitus	6.32e-07	5.43e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—AKT1—type 2 diabetes mellitus	6.31e-07	5.43e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—TGFB1—type 2 diabetes mellitus	6.31e-07	5.43e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—MMP9—type 2 diabetes mellitus	6.27e-07	5.4e-06	CbGpPWpGaD
Vandetanib—EGFR—Immune System—IL6—type 2 diabetes mellitus	6.25e-07	5.38e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—TGFB1—type 2 diabetes mellitus	6.21e-07	5.34e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—NFKB1—type 2 diabetes mellitus	6.21e-07	5.34e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—EGFR—type 2 diabetes mellitus	6.18e-07	5.32e-06	CbGpPWpGaD
Vandetanib—FYN—Disease—AKT1—type 2 diabetes mellitus	6.16e-07	5.3e-06	CbGpPWpGaD
Vandetanib—ABCC1—Disease—IL6—type 2 diabetes mellitus	6.12e-07	5.27e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—SLC2A4—type 2 diabetes mellitus	6.12e-07	5.27e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—GCG—type 2 diabetes mellitus	6.12e-07	5.27e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—EGFR—type 2 diabetes mellitus	6.09e-07	5.24e-06	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—AKT1—type 2 diabetes mellitus	6.09e-07	5.24e-06	CbGpPWpGaD
Vandetanib—LCK—Immune System—IL6—type 2 diabetes mellitus	6.03e-07	5.18e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—SRC—type 2 diabetes mellitus	6e-07	5.16e-06	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—AKT1—type 2 diabetes mellitus	5.88e-07	5.06e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—CASP3—type 2 diabetes mellitus	5.88e-07	5.06e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—VEGFA—type 2 diabetes mellitus	5.84e-07	5.03e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—SRC—type 2 diabetes mellitus	5.78e-07	4.98e-06	CbGpPWpGaD
Vandetanib—EGFR—Disease—IL6—type 2 diabetes mellitus	5.77e-07	4.97e-06	CbGpPWpGaD
Vandetanib—EGFR—Immune System—AKT1—type 2 diabetes mellitus	5.77e-07	4.96e-06	CbGpPWpGaD
Vandetanib—ABCC1—Disease—AKT1—type 2 diabetes mellitus	5.65e-07	4.86e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—VEGFA—type 2 diabetes mellitus	5.63e-07	4.85e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—PIK3R1—type 2 diabetes mellitus	5.59e-07	4.81e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—NOS3—type 2 diabetes mellitus	5.59e-07	4.81e-06	CbGpPWpGaD
Vandetanib—LCK—Disease—IL6—type 2 diabetes mellitus	5.56e-07	4.79e-06	CbGpPWpGaD
Vandetanib—LCK—Immune System—AKT1—type 2 diabetes mellitus	5.56e-07	4.78e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—MMP9—type 2 diabetes mellitus	5.55e-07	4.78e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—NFKB1—type 2 diabetes mellitus	5.49e-07	4.73e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—TGFB1—type 2 diabetes mellitus	5.36e-07	4.62e-06	CbGpPWpGaD
Vandetanib—SRC—Immune System—IL6—type 2 diabetes mellitus	5.33e-07	4.59e-06	CbGpPWpGaD
Vandetanib—EGFR—Disease—AKT1—type 2 diabetes mellitus	5.33e-07	4.58e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—GNB3—type 2 diabetes mellitus	5.28e-07	4.54e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PPARGC1A—type 2 diabetes mellitus	5.28e-07	4.54e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—HMOX1—type 2 diabetes mellitus	5.25e-07	4.52e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—CAT—type 2 diabetes mellitus	5.18e-07	4.46e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—TGFB1—type 2 diabetes mellitus	5.17e-07	4.45e-06	CbGpPWpGaD
Vandetanib—LCK—Disease—AKT1—type 2 diabetes mellitus	5.13e-07	4.42e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—PTGS2—type 2 diabetes mellitus	5.11e-07	4.4e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—EGFR—type 2 diabetes mellitus	5.07e-07	4.36e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—APOB—type 2 diabetes mellitus	5.03e-07	4.33e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—VEGFA—type 2 diabetes mellitus	4.99e-07	4.29e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—IL6—type 2 diabetes mellitus	4.92e-07	4.24e-06	CbGpPWpGaD
Vandetanib—SRC—Immune System—AKT1—type 2 diabetes mellitus	4.92e-07	4.23e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—GSTM1—type 2 diabetes mellitus	4.89e-07	4.21e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—IL6—type 2 diabetes mellitus	4.85e-07	4.18e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—LPL—type 2 diabetes mellitus	4.8e-07	4.13e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—IL6—type 2 diabetes mellitus	4.75e-07	4.09e-06	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—AKT1—type 2 diabetes mellitus	4.73e-07	4.07e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—ADCY5—type 2 diabetes mellitus	4.7e-07	4.05e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—GPX1—type 2 diabetes mellitus	4.69e-07	4.03e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—IL6—type 2 diabetes mellitus	4.68e-07	4.03e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—TGFB1—type 2 diabetes mellitus	4.58e-07	3.94e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—CD36—type 2 diabetes mellitus	4.57e-07	3.93e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—AKT1—type 2 diabetes mellitus	4.54e-07	3.91e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PPP2CA—type 2 diabetes mellitus	4.51e-07	3.88e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—EGFR—type 2 diabetes mellitus	4.49e-07	3.86e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—AKT1—type 2 diabetes mellitus	4.48e-07	3.85e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—AKT1—type 2 diabetes mellitus	4.38e-07	3.77e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—MTHFR—type 2 diabetes mellitus	4.33e-07	3.72e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—AKT1—type 2 diabetes mellitus	4.32e-07	3.71e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PPARA—type 2 diabetes mellitus	4.24e-07	3.65e-06	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—AKT1—type 2 diabetes mellitus	4.16e-07	3.58e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—AGT—type 2 diabetes mellitus	4.11e-07	3.54e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—IL6—type 2 diabetes mellitus	4.04e-07	3.48e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—CALM1—type 2 diabetes mellitus	4.04e-07	3.48e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—APOE—type 2 diabetes mellitus	4.03e-07	3.47e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—APOA1—type 2 diabetes mellitus	3.98e-07	3.43e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—IL6—type 2 diabetes mellitus	3.9e-07	3.35e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—AKT1—type 2 diabetes mellitus	3.73e-07	3.21e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—AKT1—type 2 diabetes mellitus	3.59e-07	3.09e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PPARG—type 2 diabetes mellitus	3.51e-07	3.02e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—IL6—type 2 diabetes mellitus	3.45e-07	2.97e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—INS—type 2 diabetes mellitus	3.44e-07	2.96e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—AKT1—type 2 diabetes mellitus	3.18e-07	2.74e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—ALB—type 2 diabetes mellitus	3.15e-07	2.71e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—NOS3—type 2 diabetes mellitus	3.02e-07	2.6e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PIK3R1—type 2 diabetes mellitus	3.02e-07	2.6e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PTGS2—type 2 diabetes mellitus	2.76e-07	2.37e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—AKT1—type 2 diabetes mellitus	2.57e-07	2.21e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—AKT1—type 2 diabetes mellitus	1.39e-07	1.19e-06	CbGpPWpGaD
